Montelucaste Apilif (Montelukast)

Montelukast, the active ingredient in Montelucaste Apilif, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in appropriate patients.

GNH USA supplies Montelucaste Apilif as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control respiratory allergic conditions. - Asthma: improves control of chronic airway inflammation and reduces bronchoconstriction. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by allergen exposure. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Nausea: transient episodes. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Neuropsychiatric events: depression, mood changes, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Montelucaste Apilif, consider the following safety measures. - Monitor mood changes: watch for depression or suicidal ideation. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Use caution in hepatic impairment: dose adjustment may be required. - Assess asthma control: ensure baseline therapy is optimized. - Store at room temperature: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines; awareness of interaction severity helps guide monitoring.

Major Interactions (Avoid): - Rifampin: strong CYP3A4 inducer that can lower montelukast exposure. - Phenobarbital: enzyme inducer reducing therapeutic levels.

Moderate Interactions (Monitor Closely): - Fluconazole: CYP2C9 inhibitor may increase plasma concentrations. - Zafirlukast: concurrent leukotriene modifiers can increase risk of side effects. - Beta‑agonists: additive bronchodilatory effect may require dose adjustment.